It has been recently reported that a large proportion of patients with familial amyotrophic lateral sclerosis (familial ALS) and frontotemporal dementia (FTD) are associated with a hexanucleotide (GGGGCC) repeat expansion in the first intron of C9ORF72. We have assessed 1,757 Italian sporadic ALS cases, 133 from Sardinia, 101 from Sicily, and 1,523 from mainland Italy. Sixty (3.7%) of 1,624 mainland Italians and Sicilians and 9 (6.8%) of the 133 Sardinian sporadic ALS cases carried the pathogenic repeat expansion. None of the 619 regionally-matched control samples (1,238 chromosomes) carried the expansion. Twenty-five cases (36.2%) had behavioral FTD in addition to ALS. FTD or unspecified dementia was also detected in 19 pedigrees (27.5%) in first-degree relatives of ALS patients. Cases carrying the C9ORF72 hexanucleotide expansion survived one year less than cases who did not carry this mutation. In conclusion, we found that C9ORF72 hexanucloetide repeat expansions represents a sizeable proportion of apparent sporadic ALS in the Italian and Sardinian population, representing by far the commonest mutation in Italy and the second more common in Sardinia.
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of the adult life characterized by a progressive loss of lower motor neurons at spinal and bulbar level and of upper motor neurons. Its course is invariably fatal within 3 to 5 years from onset. While 5 to 10% of cases is familial in nature (familial ALS), the majority of patients present as apparently sporadic (sporadic ALS).
Recently, we found that a large hexanucleotide (GGGGCC) repeat expansion in the first intron of C9ORF72, a gene located on chromosome 9p21, is pathogenic in a large proportion of patients with familial ALS and frontotemporal dementia (FTD) of Finnish and European ancestry (Renton et al., 2011; Dejesus-Hernandez et al., 2011) . In these families, the genetic defect is dominantly transmitted; however, mutations of this gene have also been detected in a number of patients with apparently sporadic ALS or FTD (Renton et al., 2011; Dejesus-Hernandez et al., 2011) . To date, little clinical information are available about the characteristics of apparently sporadic ALS patients carrying C9ORF72 hexanucleotide repeat expansions.
The aim of the present paper was to provide a detailed genotype-phenotype description of sporadic ALS cases carrying the expansion including age at onset, gender, site of onset, cognitive status and survival.
Methods
A total of 1,757 Italian sporadic ALS cases have been collected thorough the Italian ALS Genetic consortium (ITALSGEN), which is a collaborative effort between fifteen ALS centers throughout the Italian peninsula and the Mediterranean islands of Sicily and Sardinia. Of these, 133 were of Sardinian ancestry, 101 were from Sicily, and the remaining 1,523 were from mainland Italy. Of note, we previously reported the C9ORF72 repeat expansion status for 465 of these patients in our previous paper (Majounie et al., submitted) . All cases included in the present study had a negative family history for ALS and were negative for mutations in major ALS genes (SOD1, TARDBP and FUS). All cases had a diagnosis of definite, probable, probable laboratory-supported or possible ALS according to El Escorial revised criteria (Brooks et al., 2000) .
Controls consisted of 402 neurologically healthy subjects of mainland Italian ancestry, 61 of Sicilian ancestry and 156 of Sardinian ancestry.
The clinical history of patients found to carry the C9ORF72 expansion was systematically reviewed to identify details of the disease phenotype including gender, age of onset, disease duration, disease variant, details of family history and the presence of cognitive impairment. Formal cognitive evaluation was not systematically performed in this series. In 66 nonexpanded cases the age at onset, the site of onset and the survival were not known.
C9ORF72 analysis
A repeat-primed PCR assay was used to screen the presence of the GGGGCC hexanucleotide expansion in the first intron of C9ORF72 as described in the original paper (Renton et al, 2011) . This assay rapidly and robustly determines whether a sample carries the repeat expansion, but does not measure the actual number of repeats in the expansion. ALS-associated pathological expansions in C9ORF72 have been defined as greater than 30 repeats.
Statistical analysis
Continuous variables (i.e. age at symptom onset) were compared with t-test and discrete variable (i.e. gender, site of onset) with χ-square. Survival was calculated with Kaplan and Meier curves and compared with log-rank test, using as end point death or tracheostomy. For censored cases, the last day of follow-up was November 1, 2011. Multivariable analysis was performed with the Cox's proportional hazards model (stepwise backward). The following variables were included in the model: age (included as continuous variable), gender (male vs. female), site of onset (bulbar vs. spinal), ancestry (Italian vs. Sardinian), and C9ORF72 status (expanded vs. not expanded). A p-value <0.05 was considered significant. All calculation were made with SPSS (IBM corporation, version 17). The study was approved by the ethical committees of the participating centers. All patients signed a written informed consent.
Results

Frequency of C9ORF72 pathological repeat expansion in sporadic ALS
We tested 1,523 mainland Italian patients, 101 Sicilian patients, and 133 Sardinian patients diagnosed with sporadic ALS for the presence of the GGGGCC hexanucleotide repeat expansion of the C9ORF72 gene using a repeat-primed PCR assay. Fifty-five (3.6%) of the mainland Italians carried the pathogenic repeat expansion, whereas 5 (4.9%) of the 101 patients with Sicilian ancestry, and 9 (6.8%) of the 133 Sardinian sporadic ALS cases were carriers. None of the 402 mainland Italian, 61 Sicilian and 156 Sardinian control samples (1,238 chromosomes) carried the expansion. The median number of repeats in mainland Italian and Sicilian controls was 3 (range 0 to 23, interquartile range 0-5), and in Sardinian controls was 4 (range 0 to 12, interquartile range 0-5, see Supplemental Figure) .
Evaluation of the pedigrees of sporadic ALS carrying the pathological expansion did not reveal other cases of ALS. However, FTD or unspecified dementia was detected in firstdegree relatives of ALS patients in 19 (27.5%) pedigrees (27.5%). Moreover, we identified first degree relatives with parkinsonism in three pedigrees, and with schizophrenia in two pedigrees.
Genotype-phenotype correlation
The clinical characteristics of the sporadic ALS cases carrying C9ORF72 expansion are reported in Supplemental Table. Twenty-five cases (36.2%) had FTD in addition to their motor dysfunction. In all cases, FTD presented with behavioral symptoms, while none of the cases had features consistent with semantic dementia or progressive non-fluent aphasia. Three cases had additional clinical symptoms of parkinsonism, with positive DAT scan, and three had psychotic symptoms (hallucinations and delusions).
Gender distribution and site of onset were similar in mutated and non-mutated cases (Table  1) 
Tracheostomy-free survival
Survival of cases carrying the C9ORF72 hexanucleotide expansion was one year shorter than that of cases who did not carry this mutation (C9ORF72 expanded cases, median survival time 2.7 years, 95% c.i. 2.1 to 3.3; not expanded cases, median survival time 3.6; 95% c.i. 3.3 to 3.8; p=0.03) (Figure 2 ). The negative effect of C9ORF72 expansion on survival persisted in the Cox multivariate model (C9ORF72 status, not expanded vs. expanded, HR 1.79; 95% c.i. 1.26-2.98; p=0.008).
Discussion
C9ORF72 hexanucleotide repeat expansions have been detected in 3.7% of mainland Italian sporadic ALS of this series, which is representative of the Italian population, as it includes ALS cases originating from all Italian regions. Therefore, C9ORF72 hexanucleotide repeat expansions is by far the most common mutation in apparently sporadic ALS in the Italian population (Chiò et al., 2008; Lai et al., 2010; Del Bo et al., 2009; Corrado et al., 2010) .
The frequency of Italian SALS carrying C9ORF72 hexanucleotide repeat expansion is lower than that reported in Finland (Renton et al., 2011) , and in other north-European populations, such as Britons, Irish and Germans, as well in Caucasian Americans (Renton et al., 2010; Dejesuz-Hernandez et al 2011; Gijselinkck et al., 2012; Majounie et al., submitted) .
In sporadic ALS of Sardinian ancestry, C9ORF72 repeat expansions were more frequent than in mainland Italy, accounting for about 7% of cases, but they are less frequent than the A382T missense mutations of the TARDBP gene, which accounted for about 23% of sporadic ALS in the same population Orrù et al., 2011) . The high frequency of the C9ORF72 mutation in Sardinia is likely to be related to the 'magnification' of pathological genes in isolated populations, due to the so-called genetic drift phenomenon combined to the founder effect.
Sporadic ALS cases carrying the C9ORF72 hexanucleotide repeat expansion were phenotypically different from those not carrying the expansion. First, they were significantly younger, confirming previous observation in familial ALS patients carrying the same expansion (Chiò et al., in press; Majounie et al., submitted) . Second, they had a more aggressive clinical course, with a median survival ~1 year shorter than cases without the expansion. According to the Cox multivariable analysis, the negative effect of C9ORF72 mutations on ALS survival is independent of age and site of onset. However, we did not include in the analysis the presence of FTD, a known negative prognostic factor in ALS , which is known to have a higher frequency in ALS cases with C9ORF72 hexanucleotide repeat expansion than in those without this expansion (Renton et al., 2011; Dejesus-Hernandez et al., 2011) . Finally, one third of cases with the expansion manifested cognitive impairment, consistent with previous reports of a high rate of FTD in this patient group.
The identification of the C9ORF72 expansion in apparently sporadic ALS may have different explanations, including poor diagnosis in the past, lack of knowledge of family history, mutation carriers in previous generations dying of other diseases prior to developing motor neuron degeneration, reduced penetrance of the gene, and even varying phenotypic manifestations among mutation carriers within the same family (Traynor and Singleton, 2009 ). An incomplete penetrance of C9ORF72 has been reported in a large multinational study (Majounie et al., submitted) . However, the likely familial nature of these apparently sporadic cases is supported by several findings. First, the gender distribution of the cases carrying the C9ORF72 repeat expansion in our sporadic series is not different from what expected for an autosomal dominant mutation. Second, the frequent identification of relatives with FTD or dementia in the patients' pedigrees support the notion that the C9ORF72 hexanucleotide expansion may manifest with different motor or cognitive phenotypes in the same pedigree. This observation implies that the definition of familial ALS should be enlarged to include patients with a positive family history for FTD, modyfing the proposed criteria for definition of familial ALS . Third, previous data indicate that ALS and FTD patients carrying the C9ORF72 mutation share a common haplotype and that all cases are in fact derived from a single founder (Mok et al., 2012) .
In conclusion, we found that C9ORF72 hexanucloetide repeat expansions represents a sizeable proportion of apparent sporadic ALS in the Italian and Sardinian population, representing by far the commonest mutation in Italy and the second more common in Sardinia, after the A382T missense mutation of the TARDBP gene. The high frequency of familial aggregates of ALS and dementia in the pedigrees of these apparently sporadic cases with the C9ORF72 mutation support the notion that most of these cases are in fact familial.
An accurate study of the family history of ALS patients, as well the identification of comorbid FTD, may therefore be useful to identify clinically the possible carriers of this mutation. Cumulative probability of disease onset according to the age of patients. Comparison between sporadic ALS patients with, hexanucleotide repeat expansion of the C9ORF72 gene or unknown genetic mutation (p=0.003). Cumulative survival probability from time of disease onset. Comparison between sporadic ALS patients with hexanucleotide repeat expansion of the C9ORF72 gene and patients without known genetic mutation (p=0.023). Blue, unknown mutation; green, C9ORF72.
Marks are censored patients. 0.001 * Site of onset and age at onset were unknown in 17 not expanded cases.
